Milestone Pharmaceuticals Inc. develops and commercializes cardiovascular medicines, centered on CARDAMYST (etripamil) nasal spray. CARDAMYST is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia, or PSVT, to sinus rhythm in adults. Etripamil is also being developed for symptomatic episodic attacks associated with AFib-RVR.
Company news commonly covers CARDAMYST commercialization, payer formulary access, real-world evidence work such as the RESET-PSVT registry, cardiovascular conference presentations, regulatory updates, financial results and business updates. Milestone also reports equity inducement grants and other corporate actions tied to its Nasdaq-listed common shares.
Milestone Pharmaceuticals (Nasdaq: MIST) announced measures expected to cut operating expenses approximately 30% while preserving CARDAMYST sales coverage and clinical development. Completion is expected by the first quarter of 2027, with approximately $2 million in one-time charges. Third-quarter CARDAMYST net revenue was $963,000, up 73% from the second quarter. Net loss widened to $25.8 million from $11.9 million a year earlier.
Cash, cash equivalents and short-term investments totaled $145.4 million at September 30, 2026. Milestone expects funding into late 2028, more than one year beyond prior guidance, covering the anticipated second-half 2028 Phase 3 results for etripamil in atrial fibrillation with rapid ventricular rate. An RTW amendment extends the convertible notes’ payment-in-kind interest period to March 2029. CFO Amit Hasija and CMO David Bharucha departed the leadership team; Bharucha is transitioning to an adviser.
Milestone Pharmaceuticals (Nasdaq: MIST) granted 33,000 stock options as a hiring inducement for one new employee under its 2021 Inducement Plan.
The options were granted on November 2, 2026, at an exercise price of $0.72 per share, equal to the closing share price that day. They vest over four years: 25% on the first anniversary of the vesting commencement date, followed by 36 equal monthly installments. Vesting requires continuous service through each vesting date. The award was granted under Nasdaq Listing Rule 5635(c)(4).
Milestone Pharmaceuticals (MIST) will announce third-quarter 2026 financial results before market open on November 13, 2026, alongside a business update. The results cover the quarter ended September 30, 2026. An investor conference call and webcast will follow at 8:30 am ET, with an audio replay available in the News & Events section of the company's website.
Milestone Pharmaceuticals (MIST) announced Phase 3 subgroup data showing CARDAMYST restored normal heart rhythm in patients with recurrent PSVT after catheter ablation. PSVT is a type of sudden, rapid heartbeat. In the RAPID trial’s prior-ablation efficacy subgroup, 66.7% of etripamil-treated patients converted to normal rhythm within 30 minutes, versus 20.0% receiving placebo. Six patients received etripamil and five received placebo.
The results are descriptive; the subgroup analysis was not powered to compare treatment groups. The overall RAPID trial met its primary endpoint. Safety monitoring in the subgroup included continuous heart recordings and adverse-event reporting. CARDAMYST is FDA-approved to convert acute symptomatic PSVT episodes to normal rhythm in adults. The subgroup findings are scheduled for presentation at the AHA Scientific Sessions on November 7, 2026.
Milestone Pharmaceuticals (Nasdaq: MIST) will present etripamil data and program updates at three cardiovascular medical meetings beginning October 22, 2026.
At the CAPP National Conference in Dallas, October 22–24, presentations scheduled for October 22 cover blood pressure effects in paroxysmal supraventricular tachycardia (PSVT), a sudden fast heart rhythm, and the design of ReVeRA-301. That Phase 3 trial studies etripamil in patients with atrial fibrillation and rapid ventricular rate.
A November 2 presentation at TCT 2026 in San Diego will address combined efficacy, safety and test-dose tolerability across PSVT trials. A November 7 presentation at the AHA Scientific Sessions 2026 in Chicago will cover etripamil use in the RAPID study for recurrent PSVT after prior ablation.
Milestone Pharmaceuticals (MIST) enrolled its first European participant in ReVeRA-301, the Phase 3 trial evaluating etripamil nasal spray for AFib-RVR.
The participant enrolled through the Dutch Cardiovascular Investigator Network in the Netherlands. U.S. enrollment began in August 2026 and has expanded to Canada. The randomized, double-blind, placebo-controlled study targets approximately 150 treated patient events involving atrial fibrillation with rapid ventricular rate, or AFib-RVR. Patients will self-administer a 70 mg repeat-dose regimen in medically unsupervised settings. The primary endpoint is reduction in ventricular rate within 30 minutes; a key secondary endpoint measures patient-reported symptom improvement.
Milestone is pursuing a single-study supplemental new drug application pathway for AFib-RVR based on safety data to date. The regimen is already FDA-approved as CARDAMYST for PSVT, a different fast-heartbeat condition.
Milestone Pharmaceuticals (MIST) enrolled the first Canadian participant in its ReVeRA-301 Phase 3 trial at the Montreal Heart Institute.
The institute is the study’s first Canadian site. Enrollment there follows the first participant enrolled in the United States. The multinational, randomized, double-blind, placebo-controlled trial targets approximately 150 treated events of atrial fibrillation with rapid ventricular rate (AFib-RVR). Participants experiencing symptoms will self-administer etripamil nasal spray outside medical supervision using a 70 mg repeat-dose regimen. The primary endpoint is reduction in ventricular rate within 30 minutes; a secondary endpoint measures patient-reported symptom improvement.
The same regimen is FDA-approved as CARDAMYST for paroxysmal supraventricular tachycardia in adults, a different condition. Etripamil remains under study for AFib-RVR. In a Phase 2 emergency-room study, a single 70 mg dose reduced ventricular rate and improved symptom relief and treatment satisfaction.
Milestone Pharmaceuticals (MIST) received approval from China’s National Medical Products Administration (NMPA) for etripamil nasal spray to treat paroxysmal supraventricular tachycardia (PSVT) in adults in China, marking the first regulatory approval of etripamil outside the United States.
The decision triggers a $2.0 million milestone payment to Milestone. Everest Medicines holds exclusive rights to develop and commercialize etripamil in Greater China and, under the license, Milestone is eligible for up to $98.0 million in additional commercial and development milestones plus tiered royalties of up to 18% on future sales. Approval is supported by the global Phase 3 RAPID study and China Phase 3 JX02002 trial, where etripamil was significantly superior to placebo in converting PSVT to sinus rhythm within 30 minutes (hazard ratio 3.002; p=0.0005), with comparable adverse events to placebo and no serious adverse events within 24 hours of dosing across Phase 3 studies.
Milestone Pharmaceuticals (MIST)/b) will participate in three upcoming healthcare investor conferences in September 2026, featuring fireside chats and 1x1 meetings.Management presents at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 8 at 1:30 pm ET, and at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 15 at 10:30 am ET. Milestone will also hold 1x1 meetings at the Cantor Global Healthcare Conference in New York on September 10. Webcasts for applicable presentations will be accessible for about 90 days via the company’s website.
Milestone Pharmaceuticals (Nasdaq: MIST) reported results from a 247‑patient longitudinal web-based survey on paroxysmal supraventricular tachycardia (PSVT), presented at the ESC Congress 2026. The study evaluated how PSVT affects daily life and quality of life between episodes in adults in the United States and United Kingdom.
According to Milestone, about two-thirds of patients changed their lifestyle to avoid stress and nearly 40% reduced activity or exercise. Seventy‑three percent reported daytime activity interruption, with driving (53%) and travel (43%) commonly avoided and rated as particularly bothersome. Persistent anxiety, burdensome medication side effects, and dissatisfaction with sleep (30%) and work capacity (22%) highlight substantial quality‑of‑life impact and an unmet treatment need.